New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback